--- title: "Cue Biopharma 的股票在一夜之间飙升了超过 65%：是什么原因导致的？" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/284868524.md" description: "Cue Biopharma Inc. (CUE) 的股价上涨了 67.57%，达到 24.70 美元，此次上涨是由于公司宣布了一项 3000 万美元的私人投资、一项二期抗 IgE 抗体的许可，以及任命 Dr. Shao-Lee Lin 为首席执行官。此次 PIPE 融资将支持 Ascendant-221 的开发，这是一种抗 IgE 单克隆抗体，以及公司的整体运营需求。CUE 的市值为 4798 万美元，过去一年股价下跌了 34.92%，但目前交易价格接近其 52 周高点" datetime: "2026-05-01T05:40:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284868524.md) - [en](https://longbridge.com/en/news/284868524.md) - [zh-HK](https://longbridge.com/zh-HK/news/284868524.md) --- # Cue Biopharma 的股票在一夜之间飙升了超过 65%：是什么原因导致的？ **Cue Biopharma Inc. ( CUE )** shares surged 67.57% overnight to $24.70 on Thursday after the company simultaneously announced a $30 million private investment in public equity financing, an exclusive Phase 2 anti-IgE antibody license and a CEO appointment. ## $30 Million Raise Funds Pipeline Expansion The PIPE, expected to close around May 4, involves pre-funded warrants for up to 2.72 million shares at an effective price of $11. Net proceeds will be used to support the acquisition and development of **Ascendant-221**, a humanized anti-IgE monoclonal antibody designed to neutralize free IgE and reduce the production of new IgE, targeting major pathways involved in allergic disease. The funds will also be allocated toward general corporate purposes and working capital needs. ## Phase 2 Anti-IgE Asset Separately, CUE licensed Ascendant-221 from the biotechnology company **Ascendant Health Sciences** for a $15 million upfront fee, plus up to $676.5 million in potential development, regulatory and commercial milestone payments. The company also appointed **Shao-Lee Lin**, M.D., Ph.D., as CEO, succeeding interim chief **Lucinda Warren**. Lin previously founded biotechnology company **ACELYRIN** and took it public within three years at a valuation exceeding $2 billion, while contributing to approved medicines including TEPEZZA, SKYRIZI and RINVOQ. ## Trading Metrics, Technical Analysis Cue Biopharma ( CUE ) has a market capitalization of $47.98 million, with a 52-week high of $15.43 and a 52-week low of $0.17. The small-cap stock has declined 34.92% over the past 12 months. Cue Biopharma ( CUE ) is trading at about 95.48% of its 52-week range, indicating it remains closer to the upper end. **Price Action:** CUE closed the regular session up 13.38% at $14.74, according to Benzinga Pro. **Benzinga's Edge Stock Rankings** indicate that CUE is experiencing long-term consolidation along with medium and short-term upward movement.
_Photo courtesy: Shutterstock_ _**Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors._ **Read Also: Beyond Meat Stock Is Trending Overnight: Here's What You Should Know** ### 相关股票 - [CUE.US](https://longbridge.com/zh-CN/quote/CUE.US.md) - [SLRN.US](https://longbridge.com/zh-CN/quote/SLRN.US.md) - [BYND.US](https://longbridge.com/zh-CN/quote/BYND.US.md) ## 相关资讯与研究 - [Cue BioPharma 发布 2026 年第一季度财务业绩及近期战略进展 | CUE 股票新闻](https://longbridge.com/zh-CN/news/286460513.md) - [Cue BioPharma 第一季度净亏损收窄，研发成本降低](https://longbridge.com/zh-CN/news/286463248.md) - [Cue Biopharma 宣布进行 3000 万美元的私募 | CUE 股票新闻](https://longbridge.com/zh-CN/news/284830191.md) - [Cue BioPharma 从 Ascendant 公司获得抗 IgE 资产的许可；预付款为 1500 万美元，里程碑付款最高可达 6.765 亿美元](https://longbridge.com/zh-CN/news/284906657.md) - [美股夜盘异动：Cue Biopharma 夜盘跌 3.25%，新 CEO 任命与融资消息引发市场担忧](https://longbridge.com/zh-CN/news/285019655.md)